ArticleNucleic acids research2025
hAb-Convergent: an antibody rearrangement analysis system for therapeutic antibody engineering based on convergent evolution.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
In therapeutic antibody engineering, utilizing naturally occurring mutations in the human body as a reference for modification is an emerging trend. The theory of convergent evolution presents a viable solution. Nevertheless, the nonuniformity of the antibody rearrangement analysis system and the difficulty in identifying the heavy-chain D-region are significant challenges to research and application. To address these limitations, we developed hAb (human antibody)-Convergent, a novel tool designed to assist users in quickly identifying candidate mutation hotspots of input antibody sequences in real human immune responses for subsequent antibody engineering. It uses antibody rearrangement features-based (V, D, J genes and CDR-H3 length) rather than traditional sequence-based strategies while ensuring the security of the original sequence. Combining more inclusive D-region identification and analysis methods, it can recognize and analyze the convergence of antibodies across various individuals. Additionally, given the limitations of obtaining antibody nucleotide sequences from academic literature, it provides an optimized approach for direct analysis and rapid comparison using amino acid sequences. hAb-Convergent bridges gaps in antibody engineering by linking natural evolution patterns to in vitro design, with implications for universal vaccine development. The tool can be freely accessed at https://nmdc.cn/zoe/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.